Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07445490) titled 'Translational Potential of ex Vivo Gene Therapy in GM2 Gangliosidosis' on Feb. 25.

Study Type: Observational

Primary Sponsor: Assistance Publique - Hopitaux de Paris

Condition: Tay-Sachs Disease Ganglioside Sandhoff Disease Ganglioside

Intervention: Biological: blood sample

Recruitment Status: Not recruiting

Date of First Enrollment: May 2026

Target Sample Size: 6

Countries of Recruitment: France

To know more, visit https://clinicaltrials.gov/study/NCT07445490

Published by HT Digital Content Services with permission from Health Daily Digest....